Claims for Patent: 12,491,195

« Back to Dashboard

Summary for Patent: 12,491,195

Title:	Concentrated liquid pharmaceutical Formulations of furosemide and methods of administering the same
Abstract:	Disclosed herein, in part, are liquid pharmaceutical formulations comprising furosemide or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and a pharmaceutically acceptable buffer. Methods of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof are also provided.
Inventor(s):	Alfredo Grossi, Britt Kostraba, Olatokumbo Olajimi Luca Ogunleye, Shannon Terry, Franciscus KOPPENHAGEN
Assignee:	ScPharmaceuticals Inc
Application Number:	US18/671,025
Patent Claims:	1. A liquid pharmaceutical formulation comprising: (i) furosemide, or a pharmaceutically acceptable salt thereof; (ii) from about 0.1% (w/w) to about 30% (w/w) of one or more pharmaceutically acceptable excipients comprising benzyl alcohol; and (iii) from about 25 mM to about 100 mM of a pharmaceutically acceptable buffer comprising tromethamine or a pharmaceutically acceptable salt thereof, wherein the concentration of furosemide in the liquid pharmaceutical formulation is from about 40 mg/mL to about 250 mg/mL and the pH of the liquid pharmaceutical formulation is from about 6.5 to about 8.5. 2. The liquid pharmaceutical formulation of claim 1, wherein the one or more pharmaceutically acceptable excipients is selected from the group consisting of ethanol, glycerin, N-methyl-pyrrolidone (NMP), sodium chloride, a polyethylene glycol (PEG), propylene glycol, a polysorbate, a polyvinylpyrrolidone (PVP), a cyclodextrin, and any combination thereof. 3. A liquid pharmaceutical formulation comprising: (i) furosemide, or a pharmaceutically acceptable salt thereof; (ii) from about 0.1% (w/w) to about 10% (w/w) benzyl alcohol; and (iii) from about 25 mM to about 100 mM tromethamine or a pharmaceutically acceptable salt thereof, wherein the concentration of furosemide in the liquid pharmaceutical formulation is from about 40 mg/mL to about 250 mg/mL. 4. The liquid pharmaceutical formulation of claim 3, wherein the amount of benzyl alcohol in the liquid pharmaceutical formulation is from about 0.5% (w/w) to about 5% (w/w). 5. A liquid pharmaceutical formulation, comprising: (i) furosemide, or a pharmaceutically acceptable salt thereof; (ii) from about 0.5% (w/w) to about 5% (w/w) benzyl alcohol; and (iii) from about 50 mM to about 100 mM tromethamine or a pharmaceutically acceptable salt thereof, wherein the concentration of furosemide in the liquid pharmaceutical formulation is about 80 mg/mL and the pH of the liquid pharmaceutical formulation is from about 6.5 to about 8.5. 6. The liquid pharmaceutical formulation of claim 5, wherein the pH of the liquid pharmaceutical formulation is from about 7 to about 8. 7. A method of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof, the method comprising administering to the patient the liquid pharmaceutical formulation of claim 5. 8. The method of claim 7, wherein the liquid pharmaceutical formulation is administered to the patient by subcutaneous injection. 9. A kit for the treatment of congestion, edema, fluid overload, or hypertension comprising a liquid pharmaceutical formulation of claim 5; and instructions for treating the congestion, edema, fluid overload, or hypertension. 10. The kit of claim 9, comprising one, two, three or more units of the liquid pharmaceutical formulation. 11. The kit of claim 9, further comprising a medical device. 12. The kit of claim 11, wherein the medical device is selected from the group consisting of a needle and syringe set, an autoinjector, a single use fixed dose injection pen, a multiuse fixed dose injection pen, a single use variable dose injection pen, and a multiuse variable dose injection pen. 13. The liquid pharmaceutical formulation of claim 1, wherein the liquid pharmaceutical formulation is pre-loaded in a reservoir of a medical device. 14. The liquid pharmaceutical formulation of claim 13, wherein the medical device is selected from the group consisting of a needle and syringe set, an autoinjector, a single use fixed dose injection pen, a multiuse fixed dose injection pen, a single use variable dose injection pen, and a multiuse variable dose injection pen. 15. The liquid pharmaceutical formulation of claim 3, wherein the liquid pharmaceutical formulation is pre-loaded in a reservoir of a medical device. 16. The liquid pharmaceutical formulation of claim 15, wherein the medical device is selected from the group consisting of a needle and syringe set, an autoinjector, a single use fixed dose injection pen, a multiuse fixed dose injection pen, a single use variable dose injection pen, and a multiuse variable dose injection pen. 17. The liquid pharmaceutical formulation of claim 5, wherein the liquid pharmaceutical formulation is pre-loaded in a reservoir of a medical device. 18. The liquid pharmaceutical formulation of claim 17, wherein the medical device is selected from the group consisting of a needle and syringe set, an autoinjector, a single use fixed dose injection pen, a multiuse fixed dose injection pen, a single use variable dose injection pen, and a multiuse variable dose injection pen. 19. A kit for the treatment of congestion, edema, fluid overload, or hypertension comprising a liquid pharmaceutical formulation of claim 1; and instructions for treating the congestion, edema, fluid overload, or hypertension. 20. The kit of claim 19, comprising one, two, three or more units of the liquid pharmaceutical formulation. 21. A method of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof, the method comprising administering to the patient the liquid pharmaceutical formulation of claim 1. 22. A method of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof, the method comprising administering to the patient the liquid pharmaceutical formulation of claim 3.